Plain-English translation of NCT06562582 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a severe heart attack (called STEMI), the heart can change shape in ways that affect long-term recovery. This trial is testing three medications—bisoprolol, ramipril, and dapagliflozin—to see whether starting them right away after emergency treatment works better than waiting a week. The goal is to understand which timing helps the heart heal most effectively.
Doctors know these medications are helpful for heart attack patients, but it's unclear whether giving them immediately or waiting a few days makes a real difference in how well the heart recovers. This study will help answer that question so doctors can provide the best care from day one.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to start the medications either right away or one week after your emergency treatment. You'll have heart scans and blood tests at the beginning and one week later to measure how well your heart is recovering. The trial is designed to be simple and low-burden, fitting into your regular follow-up care after your heart attack.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Sweden
Post-approval monitoring
Sponsor
Vastra Gotaland Region
Enrollment target
~120 participants
Started
January 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Björn Redfors, Professor
Vastra Gotaland Region
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.